PBRM1 and nonpapillary renal cell carcinoma: Specifically, PBRM1 and RAD51 dual-loss ccRCC treated with immunotherapy had the lowest probability (one in 20 patients, [5.0%]) of post-treatment metastatic spread among subgroups (Fig. 3E).